Table 3.

The relationship between AIP and the risk of progression from normoglycemia to pre-DM.

Exposure	Model I (HR, 95% CI) P	Model II (HR, 95% CI) P	Model III (HR, 95% CI) P	Model IV (HR, 95% CI) P
AIP (per 0.1 unit)	1.207 (1.162, 1.254) < 0.001	1.124 (1.077, 1.174) < 0.001	1.115 (1.065, 1.167) < 0.001	1.113 (1.061, 1.167) < 0.001
AIP quartile
Q1	Ref	Ref	Ref	Ref
Q2	2.385 (1.480, 3.842) < 0.001	1.748 (1.081, 2.825) 0.023	1.727 (1.064, 2.803) 0.027	1.612 (0.986, 2.635) 0.057
Q3	4.164 (2.666, 6.505) < 0.001	2.533 (1.603, 4.001) < 0.001	2.374 (1.491, 3.779) < 0.001	2.266 (1.410, 3.642) < 0.001
Q4	5.906 (3.832, 9.103) < 0.001	3.014 (1.916, 4.742) < 0.001	2.812 (1.763, 4.486) < 0.001	2.664 (1.650, 4.301) < 0.001
P for trend	<0.001	<0.001	<0.001	<0.001

Model I: We did not adjust other covariates.

Model II: We adjust sex and age.

Model III: We adjust sex, BMI, drinking status, age, Hs-CRP, ALT, SBP, physical activity, smoking status, Scr, GGT, LDL-c, AST, hypertension, DLP-MED, and HTN-MED.

Model IV: We adjusted sex, drinking status, age (smooth), BMI (smooth), Hs-CRP (smooth), ALT (smooth), SBP (smooth), physical activity, smoking status, Scr (smooth), GGT (smooth), LDL (smooth), hypertension, AST (smooth), DLP-MED, and HTN-MED.

HR, hazard ratio; Ref, reference; CI, confidence interval.